This distributional cost-effectiveness analysis compared six MASLD fibrosis screening strategies in 15 veteran subgroups defined by race/ethnicity and social vulnerability. One strategy added an Enhanced Liver Fibrosis (ELF) blood test for indeterminate FIB-4 scores, referring those scoring above 9.80. Against standard FIB-4 screening, it cut referrals and treatment, costing screened veterans 91,370 QALYs. Counting its savings as health elsewhere at $100,000 per QALY gave the largest net gain, 185,010 QALYs. It also gave the largest fall in health inequality on the Atkinson index (0.112%). Results depended on how much of the savings was assumed to become health for other patients.
Why it is interesting: ELF screening at a lower 9.00 cutoff gave screened veterans the largest direct gains. It was not preferred once health forgone elsewhere and distributional effects were counted.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.